Standard
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. / Olsen, Ingrid Marie Holst; Sørensen, Jens B; Federspiel, Birgitte; Kjaer, Andreas; Hansen, Carsten P; Knigge, Ulrich; Langer, Seppo W.
In:
Scientific World Journal, Vol. 2012, 2012, p. 170496.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Olsen, IMH
, Sørensen, JB, Federspiel, B
, Kjaer, A, Hansen, CP
, Knigge, U & Langer, SW 2012, '
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas',
Scientific World Journal, vol. 2012, pp. 170496.
https://doi.org/10.1100/2012/170496APA
Olsen, I. M. H.
, Sørensen, J. B., Federspiel, B.
, Kjaer, A., Hansen, C. P.
, Knigge, U., & Langer, S. W. (2012).
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Scientific World Journal,
2012, 170496.
https://doi.org/10.1100/2012/170496Vancouver
Olsen IMH
, Sørensen JB, Federspiel B
, Kjaer A, Hansen CP
, Knigge U et al.
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Scientific World Journal. 2012;2012:170496.
https://doi.org/10.1100/2012/170496Author
Olsen, Ingrid Marie Holst ; Sørensen, Jens B ; Federspiel, Birgitte ; Kjaer, Andreas ; Hansen, Carsten P ; Knigge, Ulrich ; Langer, Seppo W. / Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. In: Scientific World Journal. 2012 ; Vol. 2012. pp. 170496.
Bibtex
@article{4bdfe17f293747a3b8ac8d2dd8da3ff3,
title = "Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas",
abstract = "Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.",
author = "Olsen, {Ingrid Marie Holst} and S{\o}rensen, {Jens B} and Birgitte Federspiel and Andreas Kjaer and Hansen, {Carsten P} and Ulrich Knigge and Langer, {Seppo W}",
year = "2012",
doi = "10.1100/2012/170496",
language = "English",
volume = "2012",
pages = "170496",
journal = "The Scientific World Journal",
issn = "2356-6140",
publisher = "Hindawi Publishing Corporation",
}
RIS
TY - JOUR
T1 - Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas
AU - Olsen, Ingrid Marie Holst
AU - Sørensen, Jens B
AU - Federspiel, Birgitte
AU - Kjaer, Andreas
AU - Hansen, Carsten P
AU - Knigge, Ulrich
AU - Langer, Seppo W
PY - 2012
Y1 - 2012
N2 - Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.
AB - Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.
U2 - 10.1100/2012/170496
DO - 10.1100/2012/170496
M3 - Journal article
C2 - 22973169
VL - 2012
SP - 170496
JO - The Scientific World Journal
JF - The Scientific World Journal
SN - 2356-6140
ER -
